The understanding of diffuse gliomas as discrete genetic and clinical entities has advanced markedly, and molecular testing and characterization have become an established component of the integrated diagnosis of these tumors, allowing for a more refined definition of disease and better prediction of both prognosis and therapeutic response.
The evidence-based clinical practice guideline, “Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas,” informs an integrated diagnoses of pediatric and adult patients with diffusely infiltrative gliomas. The guideline establishes 13 recommendations and three good practice statements to advise pathologists and treating physicians on the most appropriate methods, molecular biomarkers, and laboratory testing to include for optimal diagnosis, risk stratification and prognosis.
- Status: Active
- Published ahead of print: February 17, 2022
- Originally published: May 2022
Guideline Tools and Resources
American Association of Neuropathologists
Association of Molecular Pathology
Society for Neuro-Oncology
Review more CAP evidence-based guidelines by the Center.